Thousands of people suffering from migraines could soon be offered a new pill on the NHS in England.
The National Institute for Health and Care Excellence (Nice) has today published draft guidance recommending the drug Rimegepant as an option for preventing migraines in up to 145,000 adults, if previous treatments have failed. The guidance recommends that the pill, made by Pfizer, should be given to adults who have at least four migraine attacks a month but fewer than 15.
Migraine attacks usually last between four and 72 hours, according to the Migraine Society, and symptoms can include disturbed vision, sensitivity to light and sound, feeling sick and vomiting. Nice says more than 5.6 million people in England are thought to have episodic migraines and around 190,000 attacks are experienced every day.
